On Monday, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s shares declined -6.46% to $9.41.
Achillion Pharmaceuticals, Inc. (ACHN) presented two late breaker posters at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015.
Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion stated that they believe that the ability to achieve 100% SVR12 after six-weeks of treatment with ACH-3102 and sofosbuvir supports the potential for their proprietary doublet regimen to reduce treatment duration for HCV patients. They are also very happy with the robust Phase 1 proof-of-concept data stated on ACH-3422, their proprietary NS5B nucleotide polymerase inhibitor, and the clinical virology presentation that continues to support the differentiated higher barrier to resistance for ACH-3102.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s shares dropped -6.41% to $15.78.
Halozyme Therapeutics, Inc. (HALO) shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual meeting. Halozyme also declared plans to present interim results of its randomized Phase 2 study in pancreatic cancer, Study 202, next month at the annual meeting of the American Society of Clinical Oncology (ASCO).
In an oral presentation at the AACR meeting titled “Hyaluronan (HA) Depletion Enhances Tumor Accessibility of T cell and Therapeutic PD-L1 Monoclonal Antibody in HAhigh Tumors,” findings in an animal model of non-small-cell lung cancer comprised of:
- Tumors with high levels of HA – a structural carbohydrate that accumulates in the areas surrounding cancer cells -form a natural HA-rich barrier that restricted T-cell access to tumor cells.
- Halozyme’s investigational new drug, PEGPH20, depletes HA and enhances T-cells access to tumor cells in animal models.
- HA removal by PEGPH20 improved anti-PD-1 or anti-PD-L1 dependent tumor-cell killing in cell based assays.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
At the end of Monday’s trade, Sonus Networks, Inc. (NASDAQ:SONS)‘s shares dipped -6.09% to $7.95.
Sonus Networks, Inc. (SONS) declared results for the first quarter ended March 27, 2015.
First Quarter 2015 Highlights
- Total Company revenue was $50.1 million, contrast to $70.7 million in the first quarter of 2014.
- Product revenue was $24.9 million, contrast to $45.1 million in the first quarter of 2014.
- Service revenue was $25.2 million, contrast to $25.6 million in the first quarter of 2014.
- Indirect revenue was 24% of product revenue, contrast to 18% in the first quarter of 2014.
The Company’s first quarter results reflect shifts in predictable customer activity and ordering patterns, counting the deferral of certain customer purchasing decisions that had been predictable to be made at the back end of the first quarter in addition to a reduction in customer spend contrast to what had been forecast. The Company is now seeing lengthening decision cycles for both Tier 1 and midsize customers, primarily in North America.
Sonus Networks, Inc. provides networked solutions for communications service providers and enterprises. Its products comprise session border controllers (SBC) that address the network requirements for small, medium, and large businesses.
W&T Offshore, Inc. (NYSE:WTI), ended its Monday’s trading session with -6.07% loss, and closed at $5.88.
W&T Offshore, Inc. (WTI) declared that it will release its first quarter 2015 financial and operational results after the market closes on Wednesday, May 6, 2015. In conjunction with the release, the Company has planned a conference call, which will also be broadcast live over the Internet, on Thursday, May 7, 2015, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).
W&T Offshore, Inc., an independent oil and natural gas producer, together with its auxiliaries, engages in the acquisition, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas. DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.